Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Feeder

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of Medicinal Chemistry|September 1, 2010
Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroupPaul A Glossop, Charlotte A L Lane, David A Price, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPDLyn H Jones, Helen Baldock, Mark E Bunnage, et al.
Journal of Medicinal Chemistry|August 30, 2011
Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary diseasePaul A Glossop, Christine A L Watson, David A Price, et al.
Journal of Medicinal Chemistry|March 25, 2010
Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humansMark I Lansdell, David Hepworth, Andrew Calabrese, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of Medicinal Chemistry|September 1, 2010
Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroupPaul A Glossop, Charlotte A L Lane, David A Price, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPDLyn H Jones, Helen Baldock, Mark E Bunnage, et al.
Journal of Medicinal Chemistry|August 30, 2011
Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary diseasePaul A Glossop, Christine A L Watson, David A Price, et al.
Journal of Medicinal Chemistry|March 25, 2010
Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humansMark I Lansdell, David Hepworth, Andrew Calabrese, et al.
Pageof 3